TriangleBiospecimen Collection (NCT05879250)
Biospecimen Collection trial for Glioblastoma, IDH-Wildtype (NCT05879250). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with newly diagnosed, IDH-wildtype, MGMT-unmethylated glioblastoma starting within eight weeks of initial surgery or biopsy. Cohorts depend on whether the tumor was completely removed.
The idea: WP1066 targets STAT3 signaling involved in tumor growth and immune suppression. Oral treatment accompanies six weeks of radiation, followed by twelve four-week cycles. Patients with remaining tumor may undergo another operation or biopsy if eligible. Researchers assess progression, survival, immune changes, and safety.
This phase 2 study plans 39 patients. Amy Heimberger leads at Northwestern University, Chicago, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.